Sanofi, miRecule Ink Muscular Dystrophy Research Deal Worth up to $430M

miRecule inked a research partnership and licensing deal with Sanofi worth up to $430 million that will advance a best-in-class antibody-RNA conjugate (ARC) to treat facioscapulohumeral muscular dystrophy (FSHD), the companies announced Tuesday.